Evidence map›Paper›PMID 35464449›Full record

ArticleFrontiers in immunology2022

Dichotomy in Neutralizing Antibody Induction to Peptide-Conjugated Vaccine in Squalene Emulsion Contrast With Aluminum Hydroxide Formulation.

Olivia Bonduelle, Chloé Chaudesaigues, Monica Tolazzi, Ehsan Suleiman, Simon de Bernard, Karine Alves, Julien Nourikyan, Mylene Bohec, Laura G Baudrin, Dietmar Katinger and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Olivia BonduelleSorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
Chloé ChaudesaiguesSorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
Monica TolazziViral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
Ehsan SuleimanPolymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg, Austria.
Simon de BernardAltrabio, Lyon, France.
Karine AlvesAltrabio, Lyon, France.
Julien NourikyanAltrabio, Lyon, France.
Mylene BohecInstitut Curie, Genomics of Excellence (ICGex) Platform, Paris Science et Lettres (PSL) Research University, Paris, France.
Laura G BaudrinInstitut Curie, Genomics of Excellence (ICGex) Platform, Paris Science et Lettres (PSL) Research University, Paris, France.
Dietmar KatingerPolymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg, Austria.
Patrice DebréSorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
Gabriella ScarlattiViral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, Milan, Italy.
Vincent VieillardSorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
Behazine CombadièreSorbonne Université, Institut national de la santé et de la recherche médicale (Inserm) U1135, Centre d'Immunologie et des Maladies Infectieuses, Paris, France.
Centre d'Immunologie et des Maladies Infectieuses · FRIstituti di Ricovero e Cura a Carattere Scientifico · ITPolymun (Austria) · ATInstitut Curie · FRUniversité Paris Sciences et Lettres · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

W614A-3S peptide is a modified 3S motif of the HIV-gp41 (mutation W614A). We previously detected the presence of natural neutralizing antibodies directed against W614A-3S peptide (NAbs) in long-term non-progressor HIV

Indexed as

Antibodies, NeutralizingHIV InfectionsAdjuvants, ImmunologicAluminum HydroxideAnimalsBroadly Neutralizing AntibodiesEmulsionsHumansMicePeptidesRabbitsSqualeneVaccines, ConjugateVaccines, SubunitAdjuvants, ImmunologicAluminum HydroxideAntibodies, NeutralizingBroadly Neutralizing AntibodiesEmulsionsPeptidesSqualeneVaccines, ConjugateVaccines, SubunitadjuvantB-cellsneutralizingsqualenevaccine

Identifiers

PMID35464449
PMCPMC9021396
OpenAlexW4226058954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.